主页 > 医学新闻 >
【文摘发布】恶性消化系内分泌肿瘤的生存分析
Author:Lepage C, Rachet B, Coleman MP.
Resource: Gastroenterology. 2007 Mar;132(3):899-904. Epub 2007 Jan 5
Abstract: BACKGROUND AND AIMS: Little is known about the prognosis of patients with malignant digestive endocrine tumors (MDETs), primarily because of their rarity. METHODS: Survival from these tumors has been evaluated in a large, well-defined, national population. All patients diagnosed and registered in England and Wales during the 14-year period from 1986 to 1999 were followed up for vital status to the end of 2001. Relative survival was estimated and the impact of age, sex, period, histology, and anatomic site modeled. RESULTS: Among 4104 cases of MDETs, 21.2% were small cell tumors. Relative survival for all MDETs combined was 45.9% at 5 years and 38.4% at 10 years. Five-year survival was 56.8% for well-differentiated tumors but only 5.2% for small cell tumors (P < .0001). Survival was highest for large bowel tumors and lowest for esophageal tumors. Among well-differentiated pancreatic tumors, 5-year relative survival was 49.2% for insulinomas, 39.9% for gastrinomas, 17.1% for glucagonomas, 26.3% for carcinoid tumors, and 29.3% for nonfunctioning tumors. There was no difference in survival between socioeconomic groups. Five-year survival did not improve between 1986 and 2001. Survival was higher for women and for younger patients. Gender, age at diagnosis, and anatomic site were independent prognostic factors. CONCLUSIONS: The prognosis of patients with MDETs in the general population is considerably worse than is often reported from small hospital case series. Prognosis varies with tumor differentiation, anatomic site, and histologic type. Early diagnosis is difficult; new therapeutic options appear to represent the best approach to improved prognosis.
PMID:17383419 本人认领此文。如在48小时内未能提交译文，其他战友可自由认领。 Title: Survival from malignant digestive endocrine tumors in England and Wales: a population-based study.
题目：恶性消化系内分泌肿瘤的生存分析--英格兰和威尔士的人群研究
Author:Lepage C, Rachet B, Coleman MP.
作者：Lepage C, Rachet B, Coleman MP.
Resource: Gastroenterology. 2007 Mar;132(3):899-904. Epub 2007 Jan 5
来源：胃肠学.2007 Mar;132(3):899-904. Epub 2007 Jan 5
Abstract: BACKGROUND AND AIMS: Little is known about the prognosis of patients with malignant digestive endocrine tumors (MDETs), primarily because of their rarity.
摘要：背景与目的：由于恶性消化系内分泌肿瘤(MDETs)非常罕见，我们对此类疾病患者的预后知之甚少。
METHODS: Survival from these tumors has been evaluated in a large, well-defined, national population. All patients diagnosed and registered in England and Wales during the 14-year period from 1986 to 1999 were followed up for vital status to the end of 2001. Relative survival was estimated and the impact of age, sex, period, histology, and anatomic site modeled.
方法：在全国范围内对诊断明确的该病患者进行了大规模人群研究。我们于2001年末对14年间（1986－1999）英格兰和威尔士内被明确诊断并登记的病人进行了随访以评价其生存质量。我们对相对存活率进行了评价，并建立了年龄、性别、发病时间、组织学和解剖位置对存活率的影响模型。
RESULTS: Among 4104 cases of MDETs, 21.2% were small cell tumors. Relative survival for all MDETs combined was 45.9% at 5 years and 38.4% at 10 years. Five-year survival was 56.8% for well-differentiated tumors but only 5.2% for small cell tumors (P < .0001). Survival was highest for large bowel tumors and lowest for esophageal tumors. Among well-differentiated pancreatic tumors, 5-year relative survival was 49.2% for insulinomas, 39.9% for gastrinomas, 17.1% for glucagonomas, 26.3% for carcinoid tumors, and 29.3% for nonfunctioning tumors. There was no difference in survival between socioeconomic groups. Five-year survival did not improve between 1986 and 2001. Survival was higher for women and for younger patients. Gender, age at diagnosis, and anatomic site were independent prognostic factors.
结果：在4104例MDETs病例中，有21.2％为小细胞癌。所有MDETs患者5年和10年的相对生存率分别为45.9％和38.4％。分化程度良好的肿瘤5年存活率为56.8％，而小细胞癌仅为5.2％（P<0.0001）。其中大肠癌生存率最高，而食管癌则最低。在分化良好的胰腺癌中，胰岛素瘤、胃泌素瘤、胰高血糖素瘤、类癌肿瘤和无功能性肿瘤的5年存活率分别为49.2％、39.9％、17.1％、26.3％和29.3％。社会经济因素对存活率没有影响。1986到2001年间的5年存活率未见提高。女性和低龄患者存活率高。性别、确诊时年龄和解剖部位是影响预后的独立作用因素。
CONCLUSIONS: The prognosis of patients with MDETs in the general population is considerably worse than is often reported from small hospital case series. Prognosis varies with tumor differentiation, anatomic site, and histologic type. Early diagnosis is difficult; new therapeutic options appear to represent the best approach to improved prognosis.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-16 05:11
医学,生命科学网